Aspen Neuroscience Inc.
ASPEHealthcare|Biotechnology|US
$12.44
+0.68 (+5.78%)
About
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.
Stock Price
-16.5%(1Y)
1M
-16.5%
3M
-16.5%
6M
-16.5%
YTD
-16.5%
1Y
-16.5%
3Y
-16.5%
5Y
-16.5%
Pipeline Summary
1 total trials1
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
By Invitation: 1
Key Facts
Market Cap$361.7M
Employees117
CEODamien McDevitt
IPO DateOct 30, 2026
Beta0.00
52-Week Range$11.2 – $14.9
Avg Volume538,532
ExchangeNASDAQ
Websiteaspenneuroscience.com
Ownership
Float56.0%
Shares Outstanding29.1M
Recent Insider Trades
Thompson Peter A.BUY
Nov 2, 20261,000,000 shares @ $15.00
Thompson Peter A.CONVERSION
Nov 2, 2026507,119 shares
Thompson Peter A.CONVERSION
Nov 2, 2026625,743 shares
Thompson Peter A.CONVERSION
Nov 2, 2026616,984 shares
Thompson Peter A.CONVERSION
Nov 2, 2026642,745 shares
Recent News
Aspen Neuroscience (NASDAQ:ASPE) Director Acquires $15,000,000.00 in Stock
Nov 7, 2026 · defenseworld.net
Aspen Neuroscience (NASDAQ:ASPE) Director Acquires $15,000,000.00 in Stock
Nov 7, 2026 · defenseworld.net
U.S. IPO Weekly Recap: Anthropic Files For Potentially Record-Breaking IPO
Oct 31, 2026 · seekingalpha.com
Aspen Neuroscience Announces Pricing of Initial Public Offering
Oct 29, 2026 · globenewswire.com
Aspen Neuroscience Pursues IPO On Promising Parkinson's Disease Treatment Candidates
Oct 28, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 03:56 AM